CHECK-CAP overview

Check-Cap Announces Positive Results from U.S. Pilot Study of C-Scan® System Advancing towards IDE submission to the FDA, targeting initiation of U.S. pivotal study in late 2020 PR Newswire ISFIYA, Israel, Dec. 30, 2019 ISFIYA, Israel , Dec. 30, 2019 /PRNewswire/ -- Check-Cap Ltd. (the "Company" or "Check-Cap") (NASDAQ: CHEK) (NASDAQ: CHEKW), (NASDAQ: CHEKZ), a clinical stage medical diagnostics company advancing the development of the C-Scan® System, the first and only preparation-free...

Check-Cap Announces $4.75 Million Private Placement PR Newswire ISFIYA, Israel, Dec. 20, 2019 ISFIYA, Israel , Dec. 20, 2019 /PRNewswire/ -- Check-Cap Ltd. (the "Company" or "Check-Cap") (NASDAQ: CHEK) (NASDAQ: CHEKW), (NASDAQ: CHEKZ), a clinical stage medical diagnostics company advancing the development of the C-Scan® System, the first and only preparation-free ingestible scanning capsule based system for the prevention of colorectal cancer through the detection of precancerous polyps, today...

Check-Cap to Present Data at Digestive Disease Week® Demonstrating Substantial Improvement in Precancerous Polyp Detection PR Newswire ISFIYA, Israel, May 16, 2019 ISFIYA, Israel , May 16, 2019 /PRNewswire/ -- Check-Cap Ltd. (the "Company" or "Check-Cap") (NASDAQ: CHEK) (NASDAQ: CHEKW), (NASDAQ: CHEKZ), a clinical stage medical diagnostics company advancing the development of C-Scan®, the first and only preparation-free capsule based screening method for the prevention of colorectal cancer...

Check-Cap Ltd. Announces Closing of $7.5 Million Registered Direct Offering PR Newswire ISFIYA, Israel, Feb. 7, 2019 ISFIYA, Israel , Feb. 7, 2019 /PRNewswire/ -- Check-Cap Ltd. (the "Company" or "Check-Cap") (NASDAQ: CHEK) (NASDAQ: CHEKW), (NASDAQ: CHEKZ), a clinical-stage medical diagnostics company offering C-Scan®, the first and only preparation free capsule-based screening method for the prevention of colorectal cancer through the detection of precancerous polyps, today announced the...

Check-Cap Announces FDA Conditional Approval of IDE to Initiate U.S. Pilot Study of C-Scan® Study to begin upon review and approval of Institutional Review Board (IRB) PR Newswire ISFIYA, Israel, Dec. 13, 2018 ISFIYA, Israel , Dec. 13, 2018 /PRNewswire/ -- Check-Cap Ltd. (the "Company" or "Check-Cap") (NASDAQ: CHEK) (NASDAQ: CHEKW), (NASDAQ: CHEKZ), a clinical-stage medical diagnostics company offering C-Scan ® , the first and only preparation free capsule-based screening method for the...

ISFIYA, ISRAEL, June 02, 2018 (GLOBE NEWSWIRE) -- Check-Cap Ltd. (the “Company” or “Check-Cap”) (NASDAQ: CHEK, CHEKW, CHEKZ), a clinical stage medical diagnostics company engaged in the development of C-Scan®, an ingestible capsule preparation-free, colorectal cancer screening, today announced the oral presentation on the feasibility of prepless colorectal cancer (CRC) screening with the multi-center clinical study submitted for the CE Mark approval of C-Scan, received in January 2018,...

ISFIYA, Israel, May 04, 2018 (GLOBE NEWSWIRE) -- Check-Cap Ltd. (the “Company” or “Check-Cap”) (NASDAQ: CHEK, CHEKW, CHEKZ), a clinical-stage medical diagnostics company engaged in the development of C-Scan®, an ingestible capsule for preparation-free, colorectal cancer screening, today announced that it has priced an underwritten public offering of 3,189,381 units at a price to the public of $5.50 per unit, for gross proceeds of approximately $17.5 million. Each unit contains one...

Check-Cap to Present at the 29th Annual ROTH Conference on March 14, 2017 PR Newswire ISFIYA, Israel, March 1, 2017 ISFIYA, Israel , March 1, 2017 /PRNewswire/ -- Check-Cap Ltd. (the "Company" or "Check-Cap") (NASDAQ: CHEK, CHEKW), a clinical stage medical diagnostics company engaged in the development of an ingestible capsule for preparation-free, colorectal cancer (CRC) screening, today announced that Bill Densel , Chief Executive Officer, will present at the 29 th Annual ROTH Conference on...